The U.S. Department of Justice has shot back at the critics of its merger review process, rejecting accusations that it “made up” the legal, factual and economic support for its approval of the SBC/AT&T and Verizon/MCI mergers.
Given the fast-changing landscape of the U.S. workplace, attorneys in the labor and employment group at Greenberg Traurig LLP believe that keeping one step ahead of current trends is essential to helping clients stay compliant with federal, state, and local laws.
Drug maker Savient Pharmaceuticals Inc. was able to buy more time for its weight-gain treatment Oxandrin Tuesday when it persuaded a U.S. federal appeals court at the last minute to issue a temporary restraining order blocking all sales of generic versions of the drug.
The legal woes keep piling up for Ortho-McNeil Pharmaceutical Co. The manufacturer of the popular birth-control patch was back in court Tuesday to face a wrongful death lawsuit brought by a 26-year-old woman and a mass action brought on behalf of 55 women who claim the contraceptive caused blood clots and other serious illnesses.
Stirred by an ugly court battle, a bill in New Jersey that seeks to amend state law to protect transgender individuals from discrimination on the job is gaining steam.
Wiggin and Dana LLP has bolstered its health care group with the addition of Jane Lembeck Kuesel, who joins the firm’s Stamford, Conn. office as counsel.
When the U.S. Chamber of Commerce called on Womble Carlyle Sandridge & Rice to handle its amicus brief in a precedent-setting employee dispute, the agency took note of the firm’s savvy in the area, according to Womble Carlyle partner Charles A. Edwards, who heads up the firm’s labor and employment group.
In a long-running Securities Litigation Uniform Standards Act dispute that has stumped a handful of federal and state judges, an appeals court has cleared the way for an asset management firm to move forward with its claims against Kohlberg Kravis Roberts & Co., one of the world’s largest private-equity firms.
Chase Bank USA and Trilegiant Corp. agreed Monday to pay 17 states a combined $14.5 million to settle allegations that they used deceptive means to lure thousands of consumers into signing up for unwanted membership programs.
A hedge fund manager has challenged U.S. regulatory requirements, arguing his portfolio of investments is his intellectual property and therefore shouldn’t be disclosed to the U.S. Securities and Exchange Commission.
In a surprising setback for Savient Pharmaceuticals Inc., a federal judge has decided to lift a temporary restraining order granted a week earlier to the drug maker that halted the sale of all generic versions of its weight-gain drug Oxandrin.
A federal judge has imposed numerous sanctions on Health Net Inc., after the company’s “repeated and unabated discovery abuses and lack of candor” allegedly caused two ERISA cases to drag on for several years.
Connecticut Attorney General Richard Blumenthal plans to expand his antitrust investigation of the insurance industry to include Allstate Corp.'s decision to stop writing new homeowners' policies in the state.
A magistrate judge in the Eastern District of Texas granted a motion by defendants Nokia and Lucent for summary judgment of invalidity against a mobile communications patent.
If employer-focused Pitney Hardin’s labor and employment attorneys wanted to brag, they could tick off their Fortune 500 clients, the cases they have argued before the U.S. Supreme Court or the fact that a former Supreme Court justice was a partner.
Taking on a familiar rival, pharmaceutical giant Merck & Co. Inc. has shot off a pair of suits against Canadian generic drug manufacturer Apotex Inc. to block it from selling generic versions of Merck’s glaucoma treatments.
Plaintiffs firms hoping to cash in on the litigation over excessive brokers’ fees suffered a setback this week when a New Jersey district judge dismissed a class action lawsuit against private money manager Lord Abbett & Co. LLC.
Keeping generic companies at bay, drug maker Savient Pharmaceuticals Inc. has won a temporary restraining order halting the sale of all generic forms of weight-gain drug Oxandrin in its patent infringement suit against Novartis AG unit Sandoz Pharmaceuticals and Upsher-Smith Laboratories Inc.
Drug manufacturer Savient Pharmaceuticals Inc. has launched a patent infringement suit against Novartis AG unit Sandoz Pharmaceuticals and Upsher-Smith Laboratories Inc. over their generic version of Savient’s lucrative weight-gain drug, Oxandrin.
Bankrupt uniform maker Best Manufacturing Group LLC on Thursday was granted a four-month extension of its exclusive period to file a Chapter 11 reorganization plan.